Finanzas de Cronos Group Inc (CRON)CRONCronos Group Inc

Cronos Group Inc. (CRON) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Cannabis Flower, accounting for 74.0% of total sales, equivalent to $39.21M. Other significant revenue streams include Cannabis Extracts and Other. Understanding this composition is critical for investors evaluating how CRON navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Cronos Group Inc. maintains a gross margin of 53.69%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 15.92%, while the net margin is 67.28%. These profitability ratios, combined with a Return on Equity (ROE) of 6.51%, provide a clear picture of how effectively CRON converts its operational activities into shareholder value.

In the context of the broader market, CRON competes directly with industry leaders such as AVBP and BRBR. With a market capitalization of $1.25B, it holds a significant position in the sector. When comparing efficiency, CRON's gross margin of 53.69% stands against AVBP's N/A and BRBR's 27.89%. Such benchmarking helps identify whether Cronos Group Inc. is trading at a premium or discount relative to its financial performance.

In Q2 2026, Cronos reported a net revenue of $53 million, a gross profit of $28.5 million, and an adjusted EBITDA of $13.1 million, showcasing robust financial health and growth.